JP2017503850A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503850A5
JP2017503850A5 JP2016554306A JP2016554306A JP2017503850A5 JP 2017503850 A5 JP2017503850 A5 JP 2017503850A5 JP 2016554306 A JP2016554306 A JP 2016554306A JP 2016554306 A JP2016554306 A JP 2016554306A JP 2017503850 A5 JP2017503850 A5 JP 2017503850A5
Authority
JP
Japan
Prior art keywords
compound
salt
alkyl
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503850A (ja
JP6670751B2 (ja
Filing date
Publication date
Priority claimed from US14/208,657 external-priority patent/US9265765B2/en
Priority claimed from US14/341,392 external-priority patent/US9376437B2/en
Priority claimed from PCT/US2014/048241 external-priority patent/WO2015073072A1/en
Application filed filed Critical
Priority claimed from PCT/US2014/055373 external-priority patent/WO2015073109A1/en
Publication of JP2017503850A publication Critical patent/JP2017503850A/ja
Publication of JP2017503850A5 publication Critical patent/JP2017503850A5/ja
Application granted granted Critical
Publication of JP6670751B2 publication Critical patent/JP6670751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554306A 2013-11-15 2014-09-12 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法 Active JP6670751B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361904718P 2013-11-15 2013-11-15
US61/904,718 2013-11-15
US14/208,657 2014-03-13
US14/208,657 US9265765B2 (en) 2013-03-13 2014-03-13 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
USPCT/US2014/048241 2014-07-25
US14/341,392 US9376437B2 (en) 2013-03-13 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PCT/US2014/048241 WO2015073072A1 (en) 2013-11-15 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US14/341,392 2014-07-25
PCT/US2014/055373 WO2015073109A1 (en) 2013-11-15 2014-09-12 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233099A Division JP2020097577A (ja) 2013-11-15 2019-12-24 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017503850A JP2017503850A (ja) 2017-02-02
JP2017503850A5 true JP2017503850A5 (enExample) 2017-10-12
JP6670751B2 JP6670751B2 (ja) 2020-03-25

Family

ID=53057842

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016554306A Active JP6670751B2 (ja) 2013-11-15 2014-09-12 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法
JP2019233099A Pending JP2020097577A (ja) 2013-11-15 2019-12-24 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法
JP2022076459A Pending JP2022105170A (ja) 2013-11-15 2022-05-06 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法
JP2024027134A Pending JP2024059840A (ja) 2013-11-15 2024-02-27 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019233099A Pending JP2020097577A (ja) 2013-11-15 2019-12-24 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法
JP2022076459A Pending JP2022105170A (ja) 2013-11-15 2022-05-06 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法
JP2024027134A Pending JP2024059840A (ja) 2013-11-15 2024-02-27 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法

Country Status (25)

Country Link
EP (3) EP3546461B1 (enExample)
JP (4) JP6670751B2 (enExample)
KR (5) KR102318238B1 (enExample)
CN (2) CN106163524B (enExample)
AU (4) AU2014349150B2 (enExample)
BR (1) BR112016011072B1 (enExample)
CA (2) CA3204925A1 (enExample)
CY (2) CY1121628T1 (enExample)
DK (2) DK3546461T3 (enExample)
EA (1) EA033744B1 (enExample)
ES (2) ES2895600T3 (enExample)
HR (2) HRP20211653T8 (enExample)
HU (2) HUE043291T2 (enExample)
IL (6) IL311202A (enExample)
LT (2) LT3068401T (enExample)
ME (1) ME03387B (enExample)
MX (3) MX2016006318A (enExample)
PL (2) PL3068401T3 (enExample)
PT (2) PT3546461T (enExample)
RS (2) RS58745B1 (enExample)
SG (1) SG10201809189UA (enExample)
SI (2) SI3068401T1 (enExample)
SM (2) SMT202100607T1 (enExample)
TR (1) TR201906711T4 (enExample)
WO (1) WO2015073109A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163524B (zh) 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
JP6802172B2 (ja) * 2015-01-30 2020-12-16 オンコシューティクス インコーポレイテッドOncoceutics,Inc. 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
EP3496724B8 (en) * 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20220193062A1 (en) * 2018-09-12 2022-06-23 Denovo Biopharma Llc Combination of enzastaurin and inhibitors of btk and uses thereof
KR102536315B1 (ko) 2020-09-11 2023-05-25 아주대학교산학협력단 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
SG166775A1 (en) * 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20080221135A1 (en) * 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
EP2367425B1 (en) * 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
US9724337B2 (en) * 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
EP2557923A4 (en) * 2010-04-16 2013-10-23 Curis Inc TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS
EP2571877B1 (en) * 2010-05-17 2018-08-15 Boehringer Ingelheim International GmbH 1h-imidazo[4,5-c]quinolines
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
AU2012240246A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
RS65813B1 (sr) 2011-04-29 2024-08-30 Penn State Res Found Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2734568T3 (es) * 2013-03-13 2019-12-10 Oncoceutics Inc 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer
CN106163524B (zh) 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
EP3662910B1 (en) * 2014-03-31 2024-09-18 The Scripps Research Institute Pharmacophore for trail induction

Similar Documents

Publication Publication Date Title
JP2017503850A5 (enExample)
EP4328229A3 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
JP2015508103A5 (enExample)
JP2016501221A5 (enExample)
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
JP2014221779A5 (enExample)
JP2017514910A5 (enExample)
JP2016532715A5 (enExample)
EP4227304A3 (en) Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons
JP2017508782A5 (enExample)
JP2018024670A5 (enExample)
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2016528301A5 (enExample)
JP2017501237A5 (enExample)
JP2016514159A5 (enExample)
JP2011105738A5 (enExample)
JP2016518328A5 (enExample)
JP2016507581A5 (enExample)
JP2018521020A5 (enExample)
JP2015508092A5 (enExample)
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
JP2017517565A5 (enExample)
JP2016505614A5 (enExample)